Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 7537: Corporate Crimes Against Health Care Act”

The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs.

Original title: “FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable ”

CDC’s National Healthcare Safety Network is the nation’s most widely used healthcare-associated infection tracking system.

Original title: “FAQs About Enrollment”

Referred to the Subcommittee on Health.

Original title: “HR 6794: VA Medical Center Facility Transparency Act”

The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies

Original title: “Government-Owned Inventions; Availability for Licensing”

This notice acknowledges the receipt of applications from 12 hospitals that have requested a waiver of statutory requirements that would otherwise require the hospitals to enter into an agreement with their designated organ procurement organization (OPO). This notice requests comments from OPOs and the general public for our consideration in determining whether we should grant the requested waivers.

Original title: “Medicare and Medicaid Programs; Announcement of Applications From 12 Hospitals Requesting Waivers for Organ Procurement Service Area”

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 46 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Original title: “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled the Collaborating Center for Questionnaire Design and Evaluation Research (CCQDER).

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the opportunity for the public and other federal agencies to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Developmental/Methodological Projects to Improve the National Health and Nutrition Exami

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Generic Information Collection Request for Cognitive Testing and Pilot Testing for t

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection." This guidance is intended for foreign and domestic human and animal drug manufacturing establishments inspected by FDA whose drugs are regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary

Original title: “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry; Availability”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S887)

Original title: “S 4008: A bill to reauthorize programs relating to oral health promotion and disease prevention.”

Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine guidelines and angered rare disease advocates for issuing multiple high-profile drug rejections.

Original title: “Vinay Prasad, controversial FDA leader, to again depart agency”

FDA held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs to the American consumer.

Original title: “FDA Holds Meeting with States on Importation of Lower Cost Drugs ”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 7837: Most Favored Patient Act of 2026”